NIA Translational Geroscience Network: An infrastructure to facilitate geroscience‐guided clinical trials
Year: 2024
Type: article
Abstract: Aging processes are the leading risk factor for most serious diseases and disabilities across the lifespan including dementias, cancers, atherosclerosis, and frailty as well as impaired physical resilience to such stresses as infections, or surgery [1][2][3] .Conditions related to fundamental aging mechanisms are the major drivers of morbidity, mortality, and health costs but have proven difficult to control.The number of age-related chronic diseases per individual increases with aging, leading to multi-morbidity and dampening the public health impact of preventing any single age-related disease 4 .A strategy to address all of these conditions is a "root cause" approach: targeting the aging mechanisms that represent shared upstream contributors or drivers.This strategy motivates the Geroscience Hypothesis that targeting aging will delay, prevent, or alleviate these conditions as a group in contrast to the traditional one-disease-at-a-time approach.Targeting various aging mechanisms using different gerotherapeutic and lifestyle interventions has shown beneficial effect in pre-clinical models 5,6 .However, testing the Geroscience Hypothesis in clinical trials will require novel, standardized, integrated approaches, appropriate frameworks, and a workforce trained to support this innovative root cause approach.To facilitate translation of potential Gerotherapeutic interventions into clinical trials, the National Institute of Aging supported development of the Translational Geroscience Network (TGN; R33AG061456; https://www.gerosciencenetwork.org/), comprised
DOI: 10.1111/jgs.18901
Language: English
Subfield: Aging
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,760
OpenAlex ID: W4395045170